Mitigation of calcification and cytotoxicity of a glutaraldehyde-preserved bovine pericardial matrix: Improved biocompatibility after extended implantation in the subcutaneous rat model

Journal of Heart Valve Disease

Volumn 19, Issue 6, 2010, Pages 778-785

  Neethling, William M L ^a,b   Glancy, Ross ^b   Hodge, Andrew J ^b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b FREMANTLE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALAMAR BLUE DYE; BLOOD CLOTTING FACTOR 8; CALCIUM; DEOXYCHOLIC ACID; DYE; GLUTARALDEHYDE; NUCLEASE; OCTOXINOL; TRITON X 100; UNCLASSIFIED DRUG; VIMENTIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOCOMPATIBILITY; CALCIFICATION; CELL INFILTRATION; CELL PROLIFERATION; CONTROLLED STUDY; COW; CROSS LINKING; CYTOTOXICITY; FIBROBLAST; HISTOLOGY; HOST CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IMPLANTATION; IN VITRO STUDY; MALE; MINERALIZATION; NONHUMAN; ORGAN PRESERVATION; PERICARDIUM; POLYMERIZATION; PRIORITY JOURNAL; RAT; SUBCUTANEOUS FAT; TISSUE ENGINEERING;

ANIMALS; BIOCOMPATIBLE MATERIALS; BIOPROSTHESIS; CALCINOSIS; CALCIUM; CATTLE; CELL SURVIVAL; CELLS, CULTURED; CROSS-LINKING REAGENTS; FACTOR VIII; FIBROBLASTS; FIXATIVES; GLUTARAL; HEART VALVE PROSTHESIS; HUMANS; MALE; MATERIALS TESTING; MODELS, ANIMAL; PERICARDIUM; RATS; RATS, WISTAR; TIME FACTORS; TISSUE PRESERVATION; VIMENTIN;

EID: 79551484401     PISSN: 09668519     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Hubert SL, Ferrans VJ, Jones M. Tissue-derived biomaterials and their use in cardiovascular prosthetic devices. Med Prog Technol 1988-89;14:115-163 (Pubitemid 19224289)
2. Valente M, Ius P, Bortolotti U, Talenti E, Bottio T, Thiene G. Pathology of the Pericarbon bovine pericardial xenograft implanted in humans. J Heart Valve Dis 1998;7:180-189 (Pubitemid 28168496)
3. Neethling WML, Van den Heever JJ, Meyer JM, Barnard HC. Processing factors as determinants of tissue valve calcification. J Cardiovasc Surg 1992;3:285-291
4. Jamieson WR, von Lipinski O, Miyagishima RT, et al. Performance of bioprostheses and mechanical prostheses assessed by composites of valve-related complications to 15 years after mitral valve replacement. J Thorac Cardiovasc Surg 2005;129:1301-1308
5. Breuer CK, Mettler BA, Anthony T, Sales VL, Schoen FJ, Mayer JE. Application of tissue-engineering principles toward the development of a semilunar heart valve substitute. Tissue Eng 2004;10:1725-1736
6. Mendelson K, Schoen FJ. Heart valve tissue engineering: Concepts, approaches, progress, and challenges. Ann Biomed Eng 2006;34:1799-1819 (Pubitemid 44770835)
7. Hopkins RA. Tissue engineering of heart valves: Decellularized valve scaffolds. Circulation 2005;111:2712-2714
8. Simon P, Kasimir MT, Seebacher G, et al. Early failure of the tissue engineered porcine heart valve SynerGraft in pediatric patients. Eur J Cardiothorac Surg 2003;23:1002-1006
9. Goncalves AC, Griffiths LG, Anthony RV, Orton EC. Decellularization of bovine pericardium for tissue-engineering by targeted removal of xenoantigens. J Heart Valve Dis 2005;14:212-217
10. Kasimir MT, Rieder E, Seebacher G, et al. Decellularization does not eliminate thrombogenicity and inflammatory stimulation in tissue-engineered porcine heart valves. J Heart Valve Dis 2006;15:278-286
11. Ketchedjian A, Jones AL, Krueger P, et al. Recellularization of decellularized allograft scaffolds in ovine great vessel reconstructions. Ann Thorac Surg 2005;79:888-896 (Pubitemid 40288742)
12. Walles T, Puschmann C, Haverich A, Mertsching H. Acellular scaffold implantation - no alternative to tissue engineering. Int J Artif Organs 2003;26: 225-234
13. Huang-Lee LLH, Cheung DT, Nimni ME. Biochemical changes and cytotoxicity associated with degradation of polymeric glutaraldehyde derived cross-links. J Biomed Mater Res 1990;24:1185-1201
14. Neethling WM, Yadav S, Hodge AJ, Glancy R. Enhanced biostability and biocompatibility of decellularized bovine pericardium, crosslinked with an ultra-low concentration monomeric aldehyde and treated with ADAPT. J Heart Valve Dis 2008;17:456-463
15. Seifalian AM, Salacinski HJ, Punshon G, Krijgsman B, Hamilton G. A new technique for measuring the cell growth and metabolism of endothelial cells seeded on vascular prostheses. J Biomed Mater Res 2001;55:637-644
16. Al-Nasiry S, Geussens N, Hanssens M, Luyten C, Pijnenborg R. The use of Alamar Blue assay for quantitative analysis of viability, migration and invasion of choriocarcinoma cells. Hum Reprod 2007;22:1304-1309 (Pubitemid 47062799)
17. Shin M, Izumi S, Nakane PK. Multilayer peroxidase-labeled antibody method: Comparison with labeled streptavidin-biotin method, avidin- biotinperoxidase complex method, and peroxidase-antiperoxidase method. J Clin Lab Anal 1995;9:424-430
18. Harken R, Taylor WJ, LeFemine AA, et al. Aortic valve replacement with a caged ball valve. Am J Cardiol 1962;9:202-299
19. Neethling WM, Hodge AJ, Clode P, Glancy R. A multi-step approach in anti-calcification of glutaraldehyde-preserved bovine pericardium. J Cardiovasc Surg (Torino) 2006;47:711-718
20. Rossi MA, Braile DM, Teixeira MD, Souza DR, Peres LC. Lipid extraction attenuates the calcific degeneration of bovine pericardium used in cardiac valve bioprostheses. J Exp Pathol (Oxford) 1990;71:187-196
21. Kim KM. Cells, rather than extracellular matrix, nucleate apatite in glutaraldehyde-treated vascular tissue. J Biomed Mater Res 2002;59:639-645
22. Affonso da Costa FD, Dohmen PM, Lopes SV, et al. Comparison of cryopreserved homografts and decellularized porcine heterografts implanted in sheep. Artif Organs 2004;28:366-370
23. Bader A, Schilling T, Teebken OE, et al. Tissue engineering of heart valves - human endothelial cell seeding of detergent acellularized porcine valves. Eur J Cardiothorac Surg 1998;14:279-284
24. Hopkins RA. Tissue engineering of heart valves: Decellularized valve scaffolds. Circulation 2005;111:2712-2714 (Pubitemid 40791538)
25. Rieder E, Kasimir MT, Silberhumer G, et al. Decellularization protocols of porcine heart valves differ importantly in efficiency of cell removal and susceptibility of the matrix to recellularization with human vascular cells. J Thorac Cardiovasc Surg 2004;127:399-405
26. Konakci KZ, Bohle B, Blumer R, et al. Alpha-Gal on bioprostheses: Xenograft immune response in cardiac surgery. Eur J Clin Invest 2005;35:17-23
27. Courtman DW, Errett BF, Wilson GJ. The role of crosslinking in modification of the immune response elicited against xenogenic vascular acellular matrices. J Biomed Mater Res 2001;55:576-586
28. Jayakrishnan A, Jameela SR. Glutaraldehyde as a fixative in bioprostheses and drug delivery matrices. Biomaterials 1996;17:471-484
29. Simonescu DT. Prevention of calcification in bioprosthetic heart valves: Challenges and perspectives. Expert Opin Biol Ther 2004;4:1971-1985
30. Neethling WM, Glancy R, Hodge AJ. ADAPT-treated porcine valve tissue (cusp and wall) versus Medtronic Freestyle and Prima Plus: Crosslink stability and calcification behavior in the subcutaneous rat model. J Heart Valve Dis 2004;13:689-696
31. Rocchini AP, Weesner KM, Heidelberger K, Keren D, Behrendt D, Rosenthal. Porcine xenograft valve failure in children: An immunologic response. Circulation 1981;64(Suppl.II):II-162-II-171
32. Diaz-Jauanen E, Strickland RG, Williams RC. Studies of human lymphocytes in the newborn and the aged. Am J Med 1975;58:620-628
33. Human P, Zilla P. Characterization of the immuneresponse to valve bioprostheses and its role in primary tissue failure. Ann Thorac Surg 2001;71(Suppl.):S385-S388
34. Mirzaie M, Meyer T, Saalmuller A, Dalichau H. Influence of glutaraldehyde fixation on the detection of SLA-I and II antigens and calcification tendency in porcine cardiac tissue. Scand Cardiovasc J 2000;34:589-592